[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100127863":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":32,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":10,"enrollmentInfo":44,"targetDuration":10,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Bayer","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Group 1",null,[12],"Drug: Kinzal\u002FPritor (Telmisartan, BAY68-9291)",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Kinzal\u002FPritor (Telmisartan, BAY68-9291)","Patients under daily life treatment receiving Pritor according to local drug information.",[9],[20],{"name":21,"affiliation":5,"role":22},"Bayer Study Director","STUDY_DIRECTOR",[24,28],{"facility":10,"status":10,"city":25,"state":10,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Many Locations","Romania","RO",{"facility":10,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Many Location","Slovakia","SK",{"type":10,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":33,"oldOrganization":34},"Medical Affairs Therapeutic Area Head","Bayer spol.s.r.o.","100127863","surveillance-of-efficacy-and-safety-of-drug-pritor-in-patients-with-arterial-hypertension-who-do-not-tolerate-ace-inhibitor-treatment-100127863",false,"NCT00932867","Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment","SONAR","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Arterial hypertension (SBP \\\u003C 160 mmHg and DBP \\\u003C 100 mmHg)\n* Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation)\n\nInclusion criteria for the control arm (treated by ACEi):\n\n* Patients over 18 years of age\n* Arterial hypertension (SBP \\\u003C 160 mmHg and DBP \\\u003C 100 mmHg)\n* Patients, who tolerate ACEi treatment\n\nExclusion Criteria:\n\n* Cholestasis, severe hepatic insufficiency\n* Allergy to telmisartan\n* Gravidity or lactation\n\nExclusion criteria for the arm of patient treated by ACEi:\n\n* Cholestasis, severe hepatic insufficiency\n* Allergy to ACEi\n* Gravidity or lactation","ALL","18 Years",{"count":45,"type":46},3114,"ACTUAL","OBSERVATIONAL","Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment",[50],"Hypertension",[52],"Arterial Hypertension","COMPLETED","2010-04-19",{"date":56,"type":57},"2010-04-20","ESTIMATED",{"date":59,"type":10},"2007-12",{"date":61,"type":46},"2009-08",{"name":5,"class":6},2]